Skip to main content
Fig. 2 | Clinical Sarcoma Research

Fig. 2

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

Fig. 2

Event-free and overall survival for CCLG and GPOH patients. 5-year EFS rates: CCLG 43% (95% CI, 36–50%); GPOH 57% (95% CI 52–62). 5-year OS rates: CCLG 52% (95% CI 45–59%); GPOH 66% (95% CI 61–71). 10-year EFS rates: CCLG 41% (95% CI 35–48); GPOH 51% (95% CI 46–56). 10-year OS rates: CCLG 49% (95% CI 42–56); GPOH 60% (95% CI 55–65)

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329